114 related articles for article (PubMed ID: 7582512)
21. Cannabinoid receptors and reward in the rat: a conditioned place preference study.
Cheer JF; Kendall DA; Marsden CA
Psychopharmacology (Berl); 2000 Jul; 151(1):25-30. PubMed ID: 10958113
[TBL] [Abstract][Full Text] [Related]
22. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.
Freedland CS; Whitlow CT; Smith HR; Porrino LJ
Brain Res; 2003 Feb; 962(1-2):169-79. PubMed ID: 12543468
[TBL] [Abstract][Full Text] [Related]
23. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
24. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
25. The interactive role of CB(1) and GABA(B) receptors in hippocampal synaptic plasticity in rats.
Nazari M; Komaki A; Karamian R; Shahidi S; Sarihi A; Asadbegi M
Brain Res Bull; 2016 Jan; 120():123-30. PubMed ID: 26611204
[TBL] [Abstract][Full Text] [Related]
26. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration.
Nava F; Carta G; Battasi AM; Gessa GL
Br J Pharmacol; 2000 Jul; 130(6):1201-10. PubMed ID: 10903956
[TBL] [Abstract][Full Text] [Related]
27. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice.
Richardson JD; Aanonsen L; Hargreaves KM
Eur J Pharmacol; 1997 Jan; 319(2-3):R3-4. PubMed ID: 9042616
[TBL] [Abstract][Full Text] [Related]
28. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
[TBL] [Abstract][Full Text] [Related]
29. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus.
Miller AS; Sañudo-Peña MC; Walker JM
Brain Res; 1998 May; 793(1-2):7-11. PubMed ID: 9630477
[TBL] [Abstract][Full Text] [Related]
30. AM251, a selective antagonist of the CB1 receptor, inhibits the induction of long-term potentiation and induces retrograde amnesia in rats.
de Oliveira Alvares L; Genro BP; Vaz Breda R; Pedroso MF; Da Costa JC; Quillfeldt JA
Brain Res; 2006 Feb; 1075(1):60-7. PubMed ID: 16464439
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.
Meschler JP; Howlett AC; Madras BK
Psychopharmacology (Berl); 2001 Jun; 156(1):79-85. PubMed ID: 11465637
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.
DeSanty KP; Dar MS
Pharmacol Biochem Behav; 2001; 69(1-2):251-9. PubMed ID: 11420093
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A.
Petitet F; Marin L; Doble A
Neuroreport; 1996 Feb; 7(3):789-92. PubMed ID: 8733746
[TBL] [Abstract][Full Text] [Related]
35. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus.
Tzavara ET; Perry KW; Rodriguez DE; Bymaster FP; Nomikos GG
Eur J Pharmacol; 2001 Aug; 426(3):R3-4. PubMed ID: 11527547
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
37. Getting stoned without inhaling: anandamide is the brain's natural marijuana.
Stahl SM
J Clin Psychiatry; 1998 Nov; 59(11):566-7. PubMed ID: 9862600
[No Abstract] [Full Text] [Related]
38. Late phase of long-term potentiation induced by co-application of N-methyl-d-aspartic acid and the antagonist of NR2B-containing N-methyl-d-aspartic acid receptors in rat hippocampus.
Oh-Nishi A; Saji M; Satoh SZ; Ogata M; Suzuki N
Neuroscience; 2009 Mar; 159(1):127-35. PubMed ID: 19010396
[TBL] [Abstract][Full Text] [Related]
39. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716.
Terranova JP; Storme JJ; Lafon N; Péŕio A; Rinaldi-Carmona M; Le Fur G; Soubrié P
Psychopharmacology (Berl); 1996 Jul; 126(2):165-72. PubMed ID: 8856836
[TBL] [Abstract][Full Text] [Related]
40. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
Compton DR; Aceto MD; Lowe J; Martin BR
J Pharmacol Exp Ther; 1996 May; 277(2):586-94. PubMed ID: 8627535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
